Key Summary Points {#FPar1}
==================

The majority of validated approaches for the management of chronic venous disease (CVD) are relatively invasive and may be limited by patient acceptance; compression is instead usually associated with poor compliance.This systematic review assessed the efficacy and safety of sulodexide for treatment of signs and symptoms of lower extremity CVD by reviewing the literature and conducting a meta-analysis.Sulodexide had a beneficial venoactive effect on the major signs and symptoms of CVD, such as pain, cramps, heaviness and oedema, without increasing the risk of adverse events. It is also likely to exert a systemic effect on the course of CVD by interfering with inflammatory chemokines.

Introduction {#Sec1}
============

Chronic venous disease (CVD)---in the more advanced stages also referred to as chronic venous insufficiency or CVI---is a multifactorial condition of the lower limbs related to endothelial dysfunction, inflammation, vein wall remodelling, incompetent valves, venous hypertension and reflux \[[@CR1]\]. Other causes include venous outflow obstruction and failure of the calf muscle pump owing to obesity or leg immobility \[[@CR2]\]. CVD is reported to affect from 30 to 50% of women and 10--30% of men in the Caucasian population \[[@CR3]\], with slightly lower rates in Hispanic, African American and Asian individuals \[[@CR4]\].

According to the causes, CVD can be defined as congenital, primary (not associated with an identifiable mechanism of venous dysfunction) \[[@CR5]\] or secondary \[[@CR6]\] (resulting from an antecedent event, usually an episode of acute deep venous thrombosis---DVT---or trauma or other) \[[@CR2], [@CR7]\].

Primary CVD is more common than secondary, with the latter being responsible for about 18--28% of limbs with CVD \[[@CR8]\]; rarely, congenital malformations can cause CVD \[[@CR9]\].

The pathogenesis of primary CVD remains unclear. The primary abnormality appears to be genetically determined alterations of constituents of the extracellular matrix, including collagen, elastin and especially proteoglycans (both at the valvular and vein wall level). Symptoms and/or signs may appear in the presence of stable or transient risk factors causing venous hypertension with distension of veins or distortion of venous valves, such as prolonged standing, obesity, pregnancy, sedentary habits and age-related weakening of calf muscles \[[@CR10], [@CR11]\].

Recent studies showed that venous hypertension and microcirculatory stasis with the attending change of shear stress damage the glycocalyx and elicit a pro-inflammatory response. This results in recruitment of leukocytes by increased expression of---among others---intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1) as well as release of pro-inflammatory agents such as interleukin-6 (IL-6), reactive oxygen species (ROS) and matrix metalloproteinases (MMP-2, MMP-9). These, in turn, contribute to tissue remodelling by promoting the degradation of extracellular matrix proteins, resulting in altered structural integrity and function of the venous wall and valves \[[@CR1], [@CR12], [@CR13]\].

The main abnormality causing secondary CVD is the event leading to venous hypertension, in most cases DVT, causing blood flow obstruction in the location of acute thrombus and dilatation of the veins with slowing of the blood flow distal to the thrombus. The complex process of acute thrombus organisation and transformation with consecutive recanalisation also leads to increased inflammatory processes. This results in progressive vein wall damage and valvular incompetence \[[@CR14]\].

The current (CEAP) classification for chronic venous disorders combines clinical signs (C), aetiology (E), anatomical distribution (A) and physiological conditions (P) for descriptive classification of CVD \[[@CR15]\]. Clinical severity scoring and quality of life scores are instruments for longitudinal research to assess outcomes. The Revised Venous Clinical Severity Score (rVCCS) is the most advanced and combines symptoms (pain), signs (varicose veins, venous oedema, skin pigmentation, inflammation, induration, active ulcer number, duration and size) and use of compression therapy \[[@CR16], [@CR17]\].

CVD is associated with a reduced quality of life, particularly in relation to pain, physical function and mobility \[[@CR2]\]. Advanced stages of chronic venous disease (CEAP classes 4--6) are associated with chronic disability and high healthcare costs \[[@CR18]\].

The symptoms of CVD recently received specific attention and became the object of a consensus, which listed, among the more or less common symptoms, pain or aching, throbbing, tightness, heaviness, fatigue, feeling of swelling, cramps, itching, restless legs, tingling, and heat or burning sensation \[[@CR19]\]. The effect of phlebotonics on symptoms was examined in a Cochrane review \[[@CR20]\]. However, other treatments were also reported to have favourable effects on CVD symptoms, including sulodexide, for which a review has not yet been published.

Description of the Intervention {#Sec2}
-------------------------------

Guidelines indicate surgery, endovenous thermal ablation \[[@CR21]\], cyanoacrylate adhesive closure \[[@CR22]\] or sclerotherapy and mechanical compression for the treatment of CVD. However, these interventions are inconvenient for patients and the resulting effects are highly operator-dependent and could negatively affect the patients' quality of life. The level of reimbursement by the different healthcare systems is limited, if there is any. Long-term compression is associated with very limited compliance \[[@CR23]--[@CR27]\]. Pharmacological treatments, on the contrary, are well accepted by the patients, easy to administer and the patients' compliance is often good \[[@CR28]\]. Among the pharmacological treatments, sulodexide deserves special attention because of its specific characteristics.

Sulodexide comprises two fractions: a fast-moving heparin fraction (80%), which has affinity for antithrombin III, and a dermatan sulphate fraction (20%) that has affinity for heparin cofactor II \[[@CR29]\]. In clinical trials it has demonstrated efficacy in the treatment/prevention of vascular diseases associated with increased thrombotic risk, including peripheral arterial occlusive diseases \[[@CR30], [@CR31]\], post-myocardial infarction \[[@CR32]\], recurrent deep vein thrombosis \[[@CR33]--[@CR35]\] and post-thrombotic syndrome \[[@CR36], [@CR37]\].

On the basis of sulodexide's antiplatelet \[[@CR38]\], anti-inflammatory \[[@CR11], [@CR39], [@CR40]\] and anti-proteolytic \[[@CR41]\] effects, as well as the protective effect on the glycocalyx layer \[[@CR42]\], it may interfere with the pathogenesis of both primary and secondary disease in patients with CVD \[[@CR43], [@CR44]\]. In fact, sulodexide has been shown to have favourable effects on the most distressing clinical sign of CVD, venous ulcers, of different origins \[[@CR45], [@CR46]\].

Objectives {#Sec3}
----------

This systematic review was undertaken to examine the available information on the effect of sulodexide for the treatment of symptoms of lower extremity CVD. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Methods {#Sec4}
=======

Criteria for Considering Studies for this Review {#Sec5}
------------------------------------------------

We included all comparative and non-comparative trials assessing the efficacy of sulodexide in patients with CVD at any disease stage. We excluded studies that did not meet the above criteria as well as studies that exclusively monitored the size and/or frequency of venous ulcer healing, already examined in other meta-analyses \[[@CR46], [@CR47]\]. We imposed no limitation on language, journal, diagnostic criterion or CEAP class (for the studies carried out after the relevant consensus) or use of compression measures. No limitation was imposed on the use of concomitant medication either, since all studies contributing to the quali-quantitative assessment excluded the concomitant treatment with other venoactive medications/phlebotonics. The only exception was one study that used sulodexide in an open, non-parallel, add-on design with diosmin-hesperidin in the treatment of venous ulcers without reporting data relevant to this review \[[@CR48]\].

Types of Participants {#Sec6}
---------------------

Participants included consenting males and females \> 18 years of age suffering from any type of CVD, regardless of the method of diagnosis.

Types of interventions {#Sec7}
----------------------

We considered all studies in which at least one arm had been treated with oral sulodexide, alone or after a run-in period with intramuscular injections, at any dosage and for any duration of treatment.

Types of Outcome Measures {#Sec8}
-------------------------

We included studies that assessed at least one of the following outcome measures:Symptoms: pain \[scored or reported as visual analogue scale (VAS)\], cramps, paraesthesias, heaviness and total symptom score;Signs: oedema (scored or reported as volume), discoloration and skin temperature (scored);Biochemical markers (including matrix metalloproteinases and interleukins);Adverse events: number of subjects who reported adverse events, regardless of whether indicated as potentially correlated with the treatment.

Search Methods {#Sec9}
--------------

In the first instance we searched the electronic databases MEDLINE, EMBASE, CINAHL and AMED as well as the Cochrane Central Register of Controlled Trials and the World Health Organisation (WHO) International Clinical Trials Registry Platform Search Portal. To favour sensitivity, the search terms were "sulodexide", "glycosaminoglycan", "chronic venous disease", "chronic venous insufficiency" and "vascular disease". Additionally, we searched the reference lists of articles retrieved by electronic searches for additional citations and hand-searched potentially relevant journal, conference proceedings and journal supplements. The electronic search included papers published up to 30 April 2019; the complete search was concluded on 30 June 2019.

Data Collection and Analysis {#Sec10}
----------------------------

The authors independently assessed the eligibility of studies identified by the searches; disagreements were resolved by consensus.

Data Extraction and Management {#Sec11}
------------------------------

One author (AAB) extracted data from the studies; the other author (JM) checked the extracted data. Collected information includes characteristics of study participants, characteristics of intervention and control groups (where applicable) and outcome characteristics of every group of participants.

Measures of Treatment Effect {#Sec12}
----------------------------

We estimated the effects of treatment using the package meta \[[@CR49]\] in *R* \[[@CR50]\]. Dichotomous variables were examined by meta-analysis of single proportions (function *metaprop*) for pooling non-comparative studies and meta-analysis of binary outcome data (*metabin*) for pooling RCTs. Similarly, continuous variables were examined by meta-analysis of single means (*metamean*) or meta-analysis of continuous outcome data (*metacont*), respectively. Results were reported with the relevant 95% confidence intervals. When the change of continuous variables at study end was not reported, it was estimated from the initial and final values, assuming a correlation of 0.750 \[[@CR51]\]. Where needed, instead of the raw data we used the standardised mean difference \[[@CR52]\] using the method of Algina and Keselman to estimate the variance \[[@CR53]\]. All analyses were performed using the random effects model unless otherwise specified. Heterogeneity was estimated in each analysis since high heterogeneity suggests considering the results with care.

Results {#Sec13}
=======

Results of the Search {#Sec14}
---------------------

Figure [1](#Fig1){ref-type="fig"} provides a summary of the literature search results and screening process.Fig. 1Summary of the literature search and screening process

Included Studies {#Sec15}
----------------

We identified 23 studies that could provide information on the effect of sulodexide in the management of CVD \[[@CR42], [@CR44], [@CR45], [@CR48], [@CR54]--[@CR72]\], with exclusion of the studies exclusively reporting the course of venous ulcers. Whenever possible, data were retrieved from the original tables; where data were reported as graphs only, numeric data were reconstructed by analysing the graphs at high magnification with a high definition software and applying standard algorithms in *R*. Studies were published in English, Italian, Spanish, Polish, Russian and Chinese but no limitation was imposed on the language. We instead excluded studies from the quantitative synthesis when no numeric data or graphs were presented in relation to the considered outcomes \[[@CR48], [@CR66], [@CR72]\], when only mean data without an interpretable form of variance were reported \[[@CR54], [@CR55], [@CR57], [@CR58], [@CR62], [@CR69]\] and when data were reported but considered in one study only.

Overall, the studies considered in this review included 7153 participants (mean age 55 years; 68% female). The mean number of participants included per clinical trial was 300 (range 8--2263). Not all studies yielded data suitable for a quantitative synthesis; the studies providing quantitative information included 1901 participants (mean age 55.2 years; 65% female) with an average size of 140 patients per study (range 8--476).

All participants were reported to meet the respective CVD criteria of every study. Formal classification of CVD stage was reported only in seven of the most recent studies \[[@CR43], [@CR44], [@CR66], [@CR68]--[@CR70], [@CR72]\], according to the CEAP consensus \[[@CR15]\]. The C3 and C4 classes accounted for almost 70% of classified cases: C0: 0.3%; C1: 3.0%; C2: 8.4%; C3: 31.8%; C4: 36.9% (with a prevalence of C4a where the stage was split); C5: 8.7%; C6: 10.9%.

Four studies specified that investigators recommended/prescribed compression treatment \[[@CR43]--[@CR45], [@CR69]\], although one author specified that the compliance with compression was limited \[[@CR69]\].

Symptoms and signs were almost exclusively monitored by means of four- or six-level scores. Only one study measured pain with a VAS \[[@CR68]\]; the same study measured the distal oedema in cm^3^. Specialised techniques were used to measure the markers of inflammation in serum or tissue \[[@CR43], [@CR44], [@CR68], [@CR71]\].

Excluded Studies {#Sec16}
----------------

We excluded 41 studies that were originally considered as potentially eligible. The reasons for exclusion were: no clinical data reported (*n* = 13) \[[@CR12], [@CR13], [@CR29], [@CR39]--[@CR41], [@CR73]--[@CR79]\], indication other than CVD with data on CVD symptoms not available/not extractable (*n* = 13) \[[@CR80]--[@CR92]\], no extractable data on symptoms (*n* = 9) \[[@CR36], [@CR93]--[@CR101]\], preliminary partial publication (*n* = 3) \[[@CR102]--[@CR104]\], data reported but not stratified by treatment (*n* = 1) \[[@CR105]\], review (*n* = 1) \[[@CR47]\] or duplicate (*n* = 1) \[[@CR98]\].

Effects of Interventions {#Sec17}
------------------------

The effects of interventions were divided into three major groups: symptoms and signs of CVD, modifications of inflammatory markers and number of patients with adverse events. Except scoring of heaviness, biochemical markers and number of patients with adverse events, none of these variables were reported by at least two controlled studies. Consequently, the methods for combining single-arm data have been used for all variables.

Symptoms of CVD {#Sec18}
---------------

Symptoms of CVD for which at least two studies provided interpretable data were: total symptoms score \[[@CR63], [@CR68]\], pain \[[@CR56], [@CR59], [@CR61], [@CR64], [@CR65], [@CR67], [@CR68], [@CR70]\], cramps \[[@CR45], [@CR56], [@CR59], [@CR63], [@CR64], [@CR67], [@CR70]\], paraesthesia \[[@CR45], [@CR56], [@CR59], [@CR60], [@CR64], [@CR67]\] and heaviness \[[@CR45], [@CR60], [@CR61], [@CR67], [@CR70]\]. All these variables were monitored by means of scales rating the intensity 0--3 except for one study where pain was measured with the VAS \[[@CR68]\]. The total symptom score was computed by summing the individual score over a different number of symptoms in the two cases: investigator-defined number of symptoms \[[@CR63]\] or VCSS symptoms and signs \[[@CR68]\].

### Total Symptom Score {#Sec19}

The total symptom score was reported in two studies on a total 483 patients. One study used the sum of scores assigned to each of: heaviness; paraesthesias; cramps; pain that was orthostatic, clinostatic and on effort; oedema of the foot, leg and general; skin pigmentation; desquamation; eczema; alteration of annexes; hypodermitis; stasis ulcer; lymphangitis; cyanosis; venous ectasia \[[@CR63]\]. The scale ranged from 0--3, so that the total score could range from 0--51. The other study instead used the VCSS scoring system, which could range from 0 to 21 (since patients with ulcers were excluded) \[[@CR68]\]. We therefore used the standardised mean difference between baseline and month 2 \[[@CR63]\] or month 3 \[[@CR68]\] data and pooled the studies using the log-transformed means.

The result (Fig. [2](#Fig2){ref-type="fig"}) showed a definite effect associated with sulodexide, regardless of the measurement method, dosage and formulation used. The overall effect in terms of standardised mean difference was 1.63 SD \[95% confidence interval (CI): 1.18; 2.25 SD\] above zero. In absolute terms (raw change of total score), the effect can be indicated as a decrease of 7.57 (95% CI 5.92; 9.69) score points with significant heterogeneity (*I*^2^: 95.9%; *P* \< 0.0001).Fig. 2Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.1: mean decrease of total symptom score expressed as standardised mean difference using the inverse variance method

### Pain {#Sec20}

Pain was reported in 8 studies on a total of 927 patients \[[@CR56], [@CR59], [@CR61], [@CR64], [@CR65], [@CR67], [@CR68], [@CR70]\] monitored for 2 (*N* = 46) \[[@CR56], [@CR61]\], 3 (*N* = 866) \[[@CR59], [@CR64], [@CR67], [@CR68], [@CR70]\] or 6 (*N* = 15) months \[[@CR65]\]. Six studies used the conventional 0--3 scoring system \[[@CR56], [@CR59], [@CR61], [@CR64], [@CR65], [@CR67]\], one used a 0--5 scale \[[@CR70]\] and one used the visual analogue scale (VAS) \[[@CR68]\]. We used the standardised mean difference to estimate the effect, with the random effects model (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.2: mean decrease of pain expressed as standardised mean difference using the inverse variance method

The overall effect could be estimated as 2.51 SD (95% CI 1.20; 3.82 SD) with high heterogeneity (*I*^2^ 100%; *P* \< 0.0001). In absolute terms, the effect estimated after the exclusion of the trial using the VAS could be reported as a decrease of 1.74 (95% CI 1.27; 2.22) score points with high heterogeneity (*I*^2^ 98.2%; *P* \< 0.0001).

### Cramps {#Sec21}

Seven studies reported the intensity of cramps (frequently reported as "nocturnal" cramps) measured with the usual scale 0--3 \[[@CR45], [@CR56], [@CR59], [@CR63], [@CR64], [@CR67]\], except one that used the 0--5 scale \[[@CR70]\]. Overall, 1427 patients were monitored, of whom 480 were treated for 2 months \[[@CR56], [@CR63]\] and the rest for 3 months. The overall effect estimate (Fig. [4](#Fig4){ref-type="fig"}) was 1.20 score points of improvement (95% CI 0.97; 1.44) with very high heterogeneity (*I*^2^ 97.7%; *P* \< 0.0001). In this case, however, large heterogeneity was expected since the dispersion measure within each study (homogeneous population and limited score span) was mostly smaller than the differences between populations across studies.Fig. 4Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.3: mean decrease of cramps expressed as mean difference using the inverse variance method

### Paraesthesia {#Sec22}

Six studies reported the intensity of paraesthesia, measured with the usual 0--3 score scale \[[@CR45], [@CR56], [@CR59], [@CR60], [@CR64], [@CR67]\]. Overall, 747 patients were monitored, of whom 79 were treated for 2 months \[[@CR56], [@CR59]\] and the rest for 3 months. The overall effect estimate (Fig. [5](#Fig5){ref-type="fig"}) was 1.06 score points of improvement (95% CI 0.65; 1.48) with high heterogeneity (*I*^2^ 98%; *P* \< 0.0001).Fig. 5Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.4: mean decrease of paraesthesia scores expressed as mean difference using the inverse variance method

### Heaviness {#Sec23}

Five studies reported the intensity of heaviness, measured with the 0--3 score scale in four \[[@CR45], [@CR60], [@CR61], [@CR67]\] and 0--5 in the fifth \[[@CR70]\]. Overall, 948 patients were monitored, treated for 2 (95 patients) \[[@CR60], [@CR61]\] or 3 months. The overall effect estimate (Fig. [6](#Fig6){ref-type="fig"}) was 1.32 score points of improvement (95% CI 1.05; 1.69) with high heterogeneity (*I*^2^ 94%; *P* \< 0.0001).Fig. 6Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.5: mean decrease of heaviness scores expressed as mean difference using the inverse variance method

Two of the studies reporting this variable were comparative vs. calcium heparin \[[@CR61]\] or placebo \[[@CR45]\]. The result of the comparison showed a significantly greater effect with sulodexide (*P* = 0.01; Fig. [7](#Fig7){ref-type="fig"}), corresponding to a decrease of 0.28 score points (95% CI 0.07; 0.50).Fig. 7Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.1: heaviness, mean change of intensity score expressed as mean difference using the inverse variance method

Signs of CVD {#Sec24}
------------

Signs of CVD for which at least two studies provided interpretable data were: oedema \[[@CR45], [@CR56], [@CR61], [@CR63]--[@CR65], [@CR68], [@CR70]\], discoloration \[[@CR56], [@CR60], [@CR64], [@CR70]\] and skin temperature \[[@CR45], [@CR65], [@CR67]\]. The variables were scored 0--3 except for one study using a 0--5 scale \[[@CR70]\] and one in which oedema was measured as volume \[[@CR68]\].

### Oedema {#Sec25}

Eight studies reported the intensity of oedema, measured with a 0--3 score scale in six \[[@CR45], [@CR56], [@CR61], [@CR63]--[@CR65]\], with a 0--5 score scale in one \[[@CR70]\] and as volume in one \[[@CR68]\]. Overall, 1005 patients were monitored, of whom 522 were treated for 2 months \[[@CR56], [@CR61], [@CR63], [@CR65]\] and the rest for 3 months. The overall effect estimate used the standardised difference (Fig. [8](#Fig8){ref-type="fig"}) and yielded 1.54 SD of improvement (95% CI 0.97; 2.10 SDs) with high heterogeneity (*I*^2^ 99%; *P* \< 0.0001). The effect size in terms of score points could be estimated after exclusion of the study using actual volume and resulted in an improvement of 1.15 (95% CI 0.78; 1.52) score points with high heterogeneity (*I*^2^ 98%; *P* \< 0.0001).Fig. 8Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.6: mean decrease of oedema measure expressed as mean standardised difference using the inverse variance method

### Discoloration {#Sec26}

Four studies reported data on skin discoloration over a total of 418 patients, of whom 87 were treated for 2 months \[[@CR56], [@CR60]\] and the rest for 3 months \[[@CR64], [@CR70]\]. The overall effect estimate yielded an improvement of 1.06 score points (95% CI 0.16; 1.96; Fig. [9](#Fig9){ref-type="fig"}); however, the heterogeneity was high (*I*^2^ 97.6%; *P* \< 0.0001).Fig. 9Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.7: mean improvement of discoloration expressed as mean difference using the inverse variance method

### Skin Temperature {#Sec27}

Three studies reported data on skin temperature over a total of 571 patients treated for 2 (*N* = 15) \[[@CR65]\] or 3 months \[[@CR45], [@CR67]\]. The overall effect estimate yielded an improvement of 1.11 score points (95% CI 0.48; 1.74; Fig. [10](#Fig10){ref-type="fig"}) with high heterogeneity (*I*^2^ 98.5%; *P* \< 0.0001).Fig. 10Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.8: mean improvement of skin temperature expressed as mean difference using the inverse variance method

Modifications of Inflammatory Markers {#Sec28}
-------------------------------------

The only markers examined under the same conditions in at least two trials were the serum level of MMP-2 \[[@CR68], [@CR71]\] and MMP-9 \[[@CR43], [@CR68], [@CR71]\]. The effect of exposure to sulodexide on IL-6, MCP-1, s-ICAM-1 and the generation of free radicals were tested under different conditions in 3--4 different experiments in two trials \[[@CR43], [@CR44]\].

### Matrix Metalloproteinase-2 {#Sec29}

Two studies examined the level of MMP-2 in the serum of 50 patients treated for 3 (22 cases) \[[@CR68]\] or 6 months (28 cases) \[[@CR71]\]. Since both measuring methods used are known to be remarkably precise, the pooled analysis is better suited to the fixed effect model and yielded an estimate indicating a significant decrease of the MMP-2 of 30.5 ng/ml (95% CI 20.7; 40.3) (Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.9: mean decrease of matrix metalloproteinase 2 in serum of patients, expressed as mean difference using the inverse variance method and the fixed effect model

### Matrix Metalloproteinase-9 {#Sec30}

Three studies examined the level of matrix metalloproteinase-9 in serum of 61 patients treated for 2 (*N* = 11) \[[@CR43]\], 3 (*N* = 22) \[[@CR68]\], or 6 (*N* = 28) months \[[@CR71]\]. In view of the different levels of precision of the techniques used, we analysed the standardised mean difference. The combined outcome indicated a mean decrease of 2.43 (95% CI 1.33; 3.52) SDs (Fig. [12](#Fig12){ref-type="fig"}) or, in original units, 1.14 ng/ml (95% CI 0.95; 1.32) using the fixed effect model.Fig. 12Forest plot of overall mean from studies reporting a single mean. 1. Sulodexide in CVD; outcome 1.10: mean decrease of matrix metalloproteinase 9 in serum of patients, expressed as standardised mean difference using the inverse variance method

### Interleukin-6 {#Sec31}

The release of IL-6 was examined in three different experiments in the same study \[[@CR44]\]. The three tests can be considered as three independent assays of the same phenomenon and can therefore be combined in a meta-analysis. The distribution of data suggested using the fixed effect model on the standardised mean difference to avoid heterogeneity. The outcome indicated a significant (*P* \< 0.0001) decrease of IL-6 release in the cells exposed to serum from treated patients compared with the cells exposed to the serum from the same patients before treatment (controls with CVD; Fig. [13](#Fig13){ref-type="fig"}). In absolute terms, the treatment reduced the release of IL-6 by 611 (95% CI 517; 705) pg/10^5^ cells.Fig. 13Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.2: release of IL-6 in the medium, expressed as standardised mean difference using the inverse variance method and the fixed effect model

### Monocyte Chemoattractant Protein-1 {#Sec32}

The release of MCP-1 was examined in two different experiments in the same study \[[@CR44]\]. The outcome, based on the same approach as before (fixed effect model on the standardised mean difference, Fig. [14](#Fig14){ref-type="fig"}), indicated a significant (*P* \< 0.0001) decrease of MCP-1 release in the cells exposed to serum from treated patients compared with the cells exposed to the serum from the same patients before treatment (controls with CVD). In absolute terms, the treatment reduced the release of MCP-1 by 156 (95% CI 105; 207) pg/10^5^ cells.Fig. 14Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.3: release of MCP-1 in the medium, expressed as standardised mean difference using the inverse variance method and the fixed effect model

### Soluble Intercellular Adhesion Molecule-1 {#Sec33}

The release of s-ICAM-1 was examined in two different experiments in the same study \[[@CR44]\]. Using the fixed effect model on the standardised mean difference, the outcome (Fig. [15](#Fig15){ref-type="fig"}) indicated a significant (*P* \< 0.0001) decrease of s-ICAM-1 release in the cells exposed to serum from treated patients compared with the cells exposed to the serum from the same patients before treatment (controls with CVD). In absolute terms, the treatment reduced the release of s-ICAM-1 by 104 (95% CI 61; 148) pg/10^5^ cells.Fig. 15Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.4: release of s-ICAM-1 in the medium, expressed as standardised mean difference using the inverse variance method and the fixed effect model

### Generation of Free Radicals {#Sec34}

The release of free radicals into the medium was examined in two different experiments in the same study \[[@CR44]\]. The outcome, according to the fixed effect model on the standardised mean difference (Fig. [16](#Fig16){ref-type="fig"}), indicated a significant decrease (*P* \< 0.0001) of the generation of free radicals in the cell cultures exposed to serum from treated patients compared with the cells exposed to the serum from the same patients before treatment (controls with CVD). In absolute terms, the treatment reduced the generation of free radicals by 140 (95% CI 92; 186) events/10^5^ cells.Fig. 16Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.5: generation of free radicals from the culture, expressed as standardised mean difference using the inverse variance method and the fixed effect model

Number of Patients with Adverse Events {#Sec35}
--------------------------------------

The number of patients reporting adverse events, regardless of their potential correlation with treatment, was reported in two comparative trials \[[@CR45], [@CR56]\] and in six non-comparative trials \[[@CR63], [@CR64], [@CR66], [@CR67], [@CR69], [@CR70]\]. We decided not to examine the data of routine haematology, clinical chemistry and vital signs, since in the few studies in which such data have been reported, only mean data have been published, whereas no mention was made of individual clinically relevant changes that could configure an adverse event.

The analysis of all available data on the proportion of subjects reporting adverse events indicated a very low incidence: 3% (95% CI 1; 4; Fig. [17](#Fig17){ref-type="fig"}). However, the high heterogeneity (*I*^2^ 93%) and the distribution of the events across studies suggested that the overall result was the composite of two different conditions. Stratifying the proportion of patients reporting adverse events by type of study (interventional or observational; Fig. [18](#Fig18){ref-type="fig"}) clearly showed two significantly different (*P* \< 0.01) rates of reporting: 13% (95% CI 8; 18) in the interventional studies and 1% (95% CI 0; 1) in the observational studies.Fig. 17Forest plot of overall proportion from studies reporting a single proportion. 1. Sulodexide in CVD; outcome 1.11: overall proportion of patients reporting adverse events, using the inverse variance method and the random effects modelFig. 18Forest plot of overall proportion from studies reporting a single proportion. 1. Sulodexide in CVD; outcome 1.12: overall proportion of patients reporting adverse events stratified by type of study, using the inverse variance method and the random effects model

The significant difference between observational and interventional studies suggests that the observational studies can be useful to record rare adverse events but, unless well monitored, are likely to underestimate the incidence of the common adverse events.

Among the considered studies, two were comparative vs. heparan sulphate and placebo, covering a total of 270 patients \[[@CR45], [@CR56]\]. The incidence of adverse events with sulodexide in these interventional trials, one of which was double-blind vs. placebo \[[@CR45]\], did not differ from that among controls (Fig. [19](#Fig19){ref-type="fig"}): RR 1.31 (95% CI: 0.74; 2.32).Fig. 19Forest plot of comparison: 2. Sulodexide vs. controls; outcome 2.6: proportion of patients with adverse events, expressed as risk ratio using the Mantel-Haenszel method and the random effects model

Discussion {#Sec36}
==========

Summary of Main Results {#Sec37}
-----------------------

We examined and evaluated the existing evidence on the efficacy and safety of sulodexide on the symptoms and markers of chronic venous disease (CVD) with the exclusion of ulcers, which have already been reviewed elsewhere \[[@CR46], [@CR47]\]. This systematic review included 23 studies with 7153 participants; 13 studies, with 1901 participants, produced data suitable for the quantitative synthesis relevant to the efficacy evaluation; 8 studies with 3656 participants provided data for the quantitative synthesis relevant to the safety evaluation.

We could extract enough information to examine the overall effect of sulodexide on the variation of symptoms (pain, cramps, paraesthesias, heaviness and total symptom score) and of signs (oedema, discoloration and skin temperature) of CVD (Table [1](#Tab1){ref-type="table"}). The interpretation of the results on symptoms and signs is that there is an effect of sulodexide in reducing the intensity of symptoms and signs of the size of approximately 1.5--2.5 standard deviations, with the exception of discoloration, which appeared unaffected by the treatment (the confidence interval included zero).Table 1Effect of sulodexide on the symptoms and signs of CVD, expressed as standardised mean change from baseline and 95% confidence intervalSymptom/signCasesStandardised mean change from baseline95% CINotesTotal score4831.631.18; 2.25Studies contributing to the measurement used different number of symptoms to compute the sum of scoresPain9102.511.20; 3.82Cramps14271.591.16; 2.02Paraesthesia7471.130.76; 1.50Heaviness9481.951.23; 2.68Oedema10051.540.97; 2.10One study used the measurement of volume instead of the scoreDiscoloration4180.340.40; 1.08Skin temperature5711.620.82; 2.42

Consistent information could be gathered from in vitro studies examining the effect of pre-treatment with sulodexide on the release of inflammatory markers (Table [2](#Tab2){ref-type="table"}), showing inhibition of the inflammatory markers associated with CVD.Table 2Effect of sulodexide on the release of inflammatory markers in CVD, expressed as mean difference between CVD control serum and serum from sulodexide-treated CVD patients, and 95% confidence intervalMarkerCasesMean difference95% CI*P* (fixed effect model)Interleukin-619 vs. 19− 611 pg/10^5^ cells− 705; − 517*p* \< 0.0001Monocyte chemoattractant protein-113 vs. 13− 156 pg/10^5^ cells− 207; − 156*P* \< 0.0001Soluble intercellular adhesion molecule-113 vs. 13− 104 pg/10^5^ cells− 147; − 61*p* \< 0.0001Free radicals generation13 vs. 13− 140 events/10^5^ cells− 186; − 92*p* \< 0.0001

Safety was examined via the number of patients reporting adverse events. The analysis (Table [3](#Tab3){ref-type="table"}) showed a significant difference in proportion of patients reporting adverse events between interventional and observational studies. Although this may be expected, it also points to the limited reliability of observational studies, unless carefully monitored.Table 3Incidence of patients with CVD reporting adverse events during treatment with sulodexide, expressed as proportion with 95% confidence intervalType of studiesCases observedProportion reporting95% CIInterventional6600.130.08; 0.18Observational29960.010.00: 0.01Total36560.030.01; 0.04

Overall Completeness and Applicability of Evidence {#Sec38}
--------------------------------------------------

Several limitations were identified in the included studies, some of which have already been mentioned. Only seven studies staged CVD according to the CEAP classification and, of these, two studies investigated inflammatory response markers \[[@CR43], [@CR44]\], while the other five were observational studies that failed to report data on symptoms stratified by CEAP class \[[@CR66], [@CR68]--[@CR70], [@CR72]\]. Therefore, homogeneity in diagnostic criteria is limited, and potential misclassification bias cannot be ruled out. Furthermore, we were unable to perform a subgroup analysis by CVD stage because data by class were not available.

Potential Biases in the Review Process {#Sec39}
--------------------------------------

We did not perform sensitivity analyses because the available information could not change substantially. Two sensitivity analyses could have been appropriate, one to use different correlation factors in the calculation of the mean change from baseline and one to account for the effect of standard treatment provisions such as compression. However, using other (smaller) correlation factors could only have widened the confidence intervals but without affecting the point estimate. A sensitivity analysis for compression should account for three factors: in a study that recommended compression, not all patients actually received compression; all patients that used compression did not necessarily correctly follow the prescription; data were not stratified by use of compression. Consequently, we decided not to perform such analyses.

There was a high degree of heterogeneity in almost all analyses. Although there may be a clinical heterogeneity due to different diagnostic classification criteria, we believe that most of the heterogeneity is due to two major factors:No standardisation was involved in measuring variables, given the different scales that have been used, andEven when the same scale was used, the differences in perception across different countries and healthcare systems represented a source of heterogeneity across studies that were internally very consistent.

These considerations may explain why the accuracy of measurements within studies was generally very high, while the differences between different studies were often very large, thereby explaining the high heterogeneity seen in the analyses.

Agreements and Disagreements with Other Studies or Reviews {#Sec40}
----------------------------------------------------------

To date, there have been no reviews on sulodexide related to symptoms, only on ulcers \[[@CR46], [@CR47]\]. Reviews were published on phlebotonics \[[@CR20], [@CR106]\], but are not applicable to drugs with the profile of sulodexide.

Conclusions {#Sec41}
===========

Implications for Practice {#Sec42}
-------------------------

Based on the currently available information, sulodexide is a useful venoactive treatment for the management of CVD because it is effective in ulcer healing, in reducing the major symptoms and signs of CVD (particularly total symptom intensity, pain, cramps, heaviness and oedema) and in decreasing the release of the inflammatory markers present in CVD. Furthermore, the use of sulodexide was safe. Additional randomised controlled trials should be performed to attain conclusive evidence.

Implications for Research {#Sec43}
-------------------------

To date, the only validated approaches to CVD are invasive: surgery, sclerotherapy, endovascular thermal ablation, cyanoacrylate adhesive closure and compression treatment. They therefore may have limited patient acceptance. For compression, the rates of poor compliance are high. Pharmacological treatments that target the conditions altering the structural integrity of the venous wall and valves may be better tailored to the patients' demands.

Further research should focus on high-quality and properly sized randomised controlled trials, using standard staging of patients and standardised assessment of symptom severity, reporting the results also stratified by stage. The trials should be designed with a clearly set primary endpoint from which the appropriate sample size can be calculated to reduce the risk of beta error, which has influenced many studies in the past. This programme should be applied to each medication or, at least, to each homogeneous class of medications to allow estimating the risk-to-benefit ratio. Finally, it would be of relevance to include properly designed studies of the cost-utility ratio, based on quality of life data.

**Enhanced Digital Features**

To view enhanced digital features for this article go to 10.6084/m9.figshare.11590920.

Funding {#FPar2}
=======

The study was conducted with the support of Alfasigma, Italy, which did not affect the processing and the final results of this work. Alfasigma, Italy, also supported the journal's Rapid Service and Open Access fee.

Medical Writing Assistance {#FPar3}
==========================

The authors thank Matt Weitz of Springer Healthcare for reviewing the English and preparing the manuscript for submission. This assistance was funded by Alfasigma Italy.

Authorship {#FPar4}
==========

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures {#FPar5}
===========

Angelo A. Bignamini received consultancy fees from Bayer Healthcare and from Alfasigma. Jiří Matuška has nothing to disclose.

Compliance with Ethics Guidelines {#FPar6}
=================================

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability {#FPar7}
=================

All data analysed in this article are present in the original papers mentioned and are shown in the figures as original or derived data.
